Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer

Published:2022-05-01 Issue:5 Volume:8 Page:760
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Strickler John H.¹,Yoshino Takayuki²,Graham Rondell P.³,Siena Salvatore⁴,Bekaii-Saab Tanios⁵

Affiliation:

1. Duke Cancer Institute, Duke University, Durham, North Carolina

2. Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

3. Division of Laboratory Genetics and Genomics, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

4. Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda and Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy

5. Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2789766/jamaoncology_strickler_2022_rv_210015_1652478683.90144.pdf

Reference75 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.;Van Cutsem;Ann Oncol,2016

2. Current and emerging biomarkers in metastatic colorectal cancer.;Lee;Curr Oncol,2019

3. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.;Price;Eur J Cancer,2016

4. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer.;Kopetz;N Engl J Med,2019